-
Mashup Score: 0Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - 7 month(s) ago
Key Points. Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.AE burden score all
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLL - 10 month(s) ago
Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of #acalabrutinib in patients with #CLL. #leusm | @DukeCancer https://t.co/YBBbzkyo2m
-
-
Mashup Score: 1Zanubrutinib Among Patients With B-Cell Malignancies Intolerant of Other BTK Inhibitors - 1 year(s) ago
Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mazyar Shadman, MD, stated, “#zanubrutinib, a safe and viable treatment for patients with B-cell malignancies, might fill that unmet need for those who exhibit intolerance to #ibrutinib or #acalabrutinib.” Read more here: https://t.co/kugGL82drX @mshadman @fredhutch https://t.co/C9lvjWQoPi
-
-
Mashup Score: 1
Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Clinical benefit has been achieved with #zanubrutinib treatment in patients B-cell malignancies who were intolerant to #acalabrutinib. #ASH22 https://t.co/EQ8cpIV7Nb
-
-
Mashup Score: 1Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL - 1 year(s) ago
Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with chronic lymphocytic leukemia on frontline #acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, vs those on #ibrutinib, according to real-world study data. #CLL #leusm #ASH22 @LevineCancer https://t.co/eWujHtOSB7
-
-
Mashup Score: 14Frontline Chemo-Free Triplet Yields High Rates of MRD-Negative Complete Remission in MCL | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination December 10, 2022 The chemotherapy-free triplet regimen of acalabrutinib, lenalidomide, and rituximab (ALR) yielded high rates of measurable residual disease (MRD)-negative complete remission (CR) when used as a…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASH22 Chemotherapy-free triplet regimen of #acalabrutinib, #lenalidomide, and #rituximab (ALR) yields high rates of MRD-negative complete remission when used as a frontline treatment in patients with #MCL https://t.co/bYHFe6GUyW
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsJeff Porter SharmanWillamette Valley Cancer Institute and US Oncology Research Center, Eugene, ORJeff Porter Sharman, Miklos Egyed, Wojciech Jurczak, Alan P. Skarbnik, Manali K. Kamdar, Talha Munir, Laura Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Emmanuelle Ferrant, Veerendra Munugalavadla, Ting Yu, Min Hui Wang,…
Source: meetings.asco.orgCategories: Hematologists1, Latest HeadlinesTweet-
ELevate-TN: #acalabrutinib with #Obinutuzumab OS benefits better than chlorambucil obinu despite allowed cross over to acal on progression. #lymsm #leusm #ASCO22 https://t.co/bicYq8fiHD
-
-
Mashup Score: 1
Acalabrutinib appears to be generally well tolerated, although progression-free survival was relatively poor in this cohort of patients with Richter transformation. On the basis of these findings, the use of acalabrutinib monotherapy in this setting is limited; however, further assessment of acalabrutinib as part of combination-based regimens for patients with Richter transformation is warranted.
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Pleased to share #acalabrutinib in #Richters transformation in @TheLancetHaem Difficult to Rx population ORR 40% Some durable responses seen Well tolerated Targeting BTK valuable Combination + improved biomarker-driver approaches needed! #lymsm #CLL https://t.co/zWdS0he1vo https://t.co/EpMKeXDCab
-
-
Mashup Score: 0Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study - 3 year(s) ago
Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib–venetoclax and chemoimmunotherapy in an…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our Oct issue: #Acalabrutinib, #venetoclax, and #obinutuzumab as frontline treatment for chronic lymphocytic #leukaemia: a single-arm, open-label, phase 2 study #leusm #CLL https://t.co/ToJE3gN4QF
-
-
Mashup Score: 4Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study - 3 year(s) ago
Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib–venetoclax and chemoimmunotherapy in an…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Research: #Acalabrutinib, #venetoclax, and #obinutuzumab as frontline treatment for chronic lymphocytic #leukaemia: a single-arm, open-label, phase 2 study #leusm #CLL https://t.co/ToJE3gN4QF
-
Detailed safety profile of #Acalabrutinib vs #Ibrutinib in previously treated #CLL in the #ELEVATE-RR trial 👉https://t.co/Y7bNzp0oC7 @MDedgeHemOnc #RiskBenefit https://t.co/2gnp1gfK4v